Covidien (COV) Tops Q4 EPS by 10c; Gives Slight Boost to FY12 Revs Outlook

Covidien (NYSE: COV) reported Q4 EPS of $1.13, $0.10 better than the analyst estimate of $1.03. Revenue for the quarter came in at $2.9 billion versus the consensus estimate of $2.92 billion.

On an operational basis, excluding the impact of foreign exchange, Covidien now estimates that total Company sales in FY12 will increase 3% to 5% in fiscal 2012, about one percentage point above its prior guidance.

For earnings history and earnings-related data on Covidien (COV) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• McDonald’s posts better-than-expected third-quarter comparable sales
• L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
• Fidelity National Information Services, Inc. (FIS) Tops Q3 EPS by 1c ; Offers Guidance